202 related articles for article (PubMed ID: 15177848)
1. Mechanisms of resistance among respiratory tract pathogens.
Jacobs MR; Anon J; Appelbaum PC
Clin Lab Med; 2004 Jun; 24(2):419-53. PubMed ID: 15177848
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
Sahm DF; Brown NP; Thornsberry C; Jones ME
Postgrad Med; 2008 Sep; 120(3 Suppl 1):16-24. PubMed ID: 18931467
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.
Mendes C; Kiffer CR; Blosser-Middleton RS; Jones ME; Karlowsky JA; Barth A; Rossi F; Andrade S; Sader HS; Thornsberry C; Sahm DF;
Clin Microbiol Infect; 2004 Jun; 10(6):521-6. PubMed ID: 15191379
[TBL] [Abstract][Full Text] [Related]
4. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
Inoue M; Kohno S; Kaku M; Yamaguchi K; Igari J; Yamanaka K
Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
[TBL] [Abstract][Full Text] [Related]
5. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
Sahm DF; Brown NP; Draghi DC; Evangelista AT; Yee YC; Thornsberry C
Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program.
Beekmann SE; Heilmann KP; Richter SS; García-de-Lomas J; Doern GV;
Int J Antimicrob Agents; 2005 Feb; 25(2):148-56. PubMed ID: 15664485
[TBL] [Abstract][Full Text] [Related]
7. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
10. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
Appelbaum PC
Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
[TBL] [Abstract][Full Text] [Related]
11. Macrolide resistance in Streptococci and Haemophilus influenzae.
Bozdogan B; Appelbaum PC
Clin Lab Med; 2004 Jun; 24(2):455-75. PubMed ID: 15177849
[TBL] [Abstract][Full Text] [Related]
12. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens.
Alpuche C; Garau J; Lim V
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S135-8. PubMed ID: 17945468
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
Elshafie SS; Al-Kuwari J
Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
[No Abstract] [Full Text] [Related]
15. Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections.
Nicolau DP
Am J Manag Care; 2004 Oct; 10(12 Suppl):S381-8. PubMed ID: 15603247
[No Abstract] [Full Text] [Related]
16. Resistance patterns of selected respiratory tract pathogens in Poland.
Skoczyńska A; Kadłubowski M; Waśko I; Fiett J; Hryniewicz W
Clin Microbiol Infect; 2007 Apr; 13(4):377-83. PubMed ID: 17359321
[TBL] [Abstract][Full Text] [Related]
17. Macrolide resistance rates in respiratory pathogens in Slovenia following reduced macrolide use.
Cizman M; Beović B; Seme K; Paragi M; Strumbelj I; Müller-Premru M; Cad-Pecar S; Pokorn M
Int J Antimicrob Agents; 2006 Dec; 28(6):537-42. PubMed ID: 17101264
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
Nord CE; Lindmark A; Persson I
J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
[No Abstract] [Full Text] [Related]
19. Microbial interactions in the respiratory tract.
Murphy TF; Bakaletz LO; Smeesters PR
Pediatr Infect Dis J; 2009 Oct; 28(10 Suppl):S121-6. PubMed ID: 19918134
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study.
Jacobs MR; Bajaksouzian S; Windau A; Good CE; Lin G; Pankuch GA; Appelbaum PC
Clin Lab Med; 2004 Jun; 24(2):503-30. PubMed ID: 15177851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
